1.93  -0.02 (-1.03%)		01-30 16:00
Open: 1.99 High: 2.1999 Volume: 34,745		Pre. Close: 1.95 Low: 1.8 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	4.47	1-year :	5.93
Resists	First :	3.83	Second :	5.08
Pivot price	3
Supports	First :	1.79	Second :	1.49
MAs	MA(5) :	2.09	MA(20) :	3.33
	MA(100) :	5.35	MA(250) :	8.63
MACD	MACD :	-0.8	Signal :	-0.7
%K %D	K(14,3) :	5.8	D(3) :	4.6
RSI	RSI(14): 24.9
52-week	High :	34.65	Low :	1.79

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ABP ] has closed above bottom band by 14.3%. Bollinger Bands are 41.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.2 - 2.22	2.22 - 2.23
Low:	1.77 - 1.78	1.78 - 1.79
Close:	1.91 - 1.93	1.93 - 1.95

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Wed, 28 Jan 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Wed, 21 Jan 2026
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Thu, 15 Jan 2026
New HER2 T-cell drug ABP-102 moves toward global trial after FDA nod - Stock Titan

Thu, 15 Jan 2026
Abpro’s Lead Program ABP-102 Featured in Celltrion - GlobeNewswire

Tue, 06 Jan 2026
Abpro stock rises after FDA clearance for solid tumor program - Investing.com

Tue, 06 Jan 2026
Experimental HER2 cancer drug clears first FDA hurdle for human testing - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	2 (M)
Held by Insiders	34.9 (%)
Held by Institutions	2.9 (%)
Shares Short	10 (K)
Shares Short P.Month	33 (K)

EPS	-8.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-6.04
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-229.6 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0.55
Sales Per Share	0
EBITDA (p.s.)	-3.42
Qtrly Earnings Growth	0 %
Operating Cash Flow	-9 (M)
Levered Free Cash Flow	6 (M)

PE Ratio	-0.24
PEG Ratio	0
Price to Book value	-0.32
Price to Sales	0
Price to Cash Flow	-0.58

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.